Time and Place
Thursday, 10.12.2020, 15:00 – 17:00 (3 - 5 p.m. CET)
Digitally delivered (GoToWebinar®)
With a market volume of USD 485 billion, the USA is one of the most lucrative and innovative markets for the pharmaceutical industry. Even with the fact that in the medium term world market shares are increasingly shifting towards emerging markets, it is still the heart of Big Pharma. All big pharmaceutical companies have started their business there or have a major presence in the US. The lack of strict price regulation allows companies to achieve record profits and at the same time many of their research and development projects are subsidized by the government.
The new president is expected to lead the country through the next four years, with the biggest challenge being to counter a pandemic that has so far claimed more than 280,000 lives in the United States. Drug prices and access will be high on the agenda, with patients and industry alike at stake. Are strict measures to enforce the regulation of drug prices to be expected? What are the prospects of drug development becoming more self-sustaining in the future - a question many nations are asking themselves as a result of the pandemic.
Many good reasons that make it worthwhile to take a look at this interesting market.
Get an insight into:
- the US market, the authorities and other players
- the admission requirements and responsibilities
- the impact of Covid-19
- options to find good and loyal local business partners and more …
This WebSeminar is intended for staff from Business Development, International Sales, Export APAC and Regulatory Affairs.
Moderator / Speakers & Abstracts
Janet Danisman Sutherland - Executive Director at Bavarian U.S. Offices East/ Invest in Bavaria and German Honorary Consul, CT & RI
Jan Danisman is the Executive Director East, of the Bavarian US Offices for Economic Development. For fifteen years Jan has been supporting US companies across the tech, life science, industrial, automotive and energy sectors with European/EMEA expansion plans with a focus on Bavaria Germany. Together with her team she founded the organization’s Expand 2 Europe web-based program, to help growth stage companies with the ins and outs of forming a successful business location in Germany. Jan is also the German Honorary Consul in Connecticut and Rhode Island focusing on transatlantic relations. Jan previously worked for an IBM business partner, Mercedes Benz and Kendall Healthcare (currently Medtronic). She has a BA and an MBA from Northeastern University.
The Bavarian US Offices for Economic Development are the US representative offices for Invest in Bavaria a division of the German State of Bavaria’s Ministry of Economy. We assist US companies to expand to Bavaria and Bavarian companies to expand into the US. With cross-cultural teams in New York, San Francisco, Boston and New Haven, CT, we are part of Invest in Bavaria’s 26 outposts globally.
Mark Lesselroth - CEO of BioPortUSA
Mark is the President and CEO of BioPortUSA, an international business development consultancy specializing in facilitating United States market entry for foreign-based life sciences companies. He has been instrumental in securing and building relationships for international clients such as Siemens, Lundbeck and GE while bridging Trans Atlantic relations involving foreign trade and investment. He has been a featured presenter at BIO, Medica and Upgraded Health. Mark is a peer reviewer for the Johns Hopkins Bloomberg School of Public Health and is an active participant in several life science clusters both in the USA and Europe.
Karsten Risch - CMO at Evoke Group
Karsten is the Chief Medical at Evoke Group. Prior to Evoke he was the Chief Medical Officer of Havas Health & You, a leading global healthcare communications group, where he implemented standard medical approaches across the organization and, over ten years, organically grew the department by than 600%. As a scholar of the German National Merit Foundation (Studienstiftung des deutschen Volkes) he studied in Göttingen, Paris, and Heidelberg, where he got his MD and PhD (anthropology and human genetics). Karsten also holds an MPH (healthcare policy and management) of the Mailman School of Public Health at Columbia University, New York. After working as global product manager at Schering AG (now Bayer HealthCare) in Berlin Karsten moved to New York City. His work in management consulting, strategic planning, and medical direction at WPP, IPG, and Havas, lead him to the Coalition for Healthcare Communication (CHC), the association of US healthcare agencies, publishers, and associations, which he presented as its chairman in 2018 and 2019. Karsten is a frequent guest lecturer at Columbia Business School, Columbia School of Public Health, Icahn School of Medicine at Mt. Sinai, New York, and Farleigh Dickinson University, New Jersey.
Charlie Cameron - SVP of Business Development at Cooley LLP | Founder/Managing Director of Hub Angel Investment Group
Charlie is a seasoned business professional with two decades of helping technology companies in all industries on their growth and financing strategies. His background includes management consulting and strategy and marketing experience prior to joining Cooley. This includes extensive consulting, board work, mentoring and coaching with early-stage, venture-backed and Fortune 500 firms. Having worked in more than 40 countries he brings a global perspective to business, marketing and entrepreneurship.
Charlie is on the board of the German-American Business Council, Boston, on the advisory boards of the German Accelerator Life Science and Charite Entrepreneurship Summit, and has built an extensive network of entrepreneurs, VCs, angel groups, bankers, lawyers and accountants. Charlie is founder and managing director of Hug Angels Investment Group which is on the sixth fund. His perspective on business issues offers a strategic perspective.
Dean Farmer – Partner at Cooley LLP
Dean works with a wide range of pharmaceutical/biotech companies including start-up biotechnology companies, mid-size pharmaceutical companies with early funding and NCEs moving into Phase I clinical trial, and larger established pharmaceutical/biotech companies in need of extensive portfolio management. His extensive knowledge of science and intellectual property (IP) law enables him to understand the challenges that his clients face and to guide them through the risks associated with IP. He and his family lived in Berlin for a number of years and he speaks German. He does significant work with life science companies and groups in DACH countries.
Many German life science companies want to make connections in Boston. Why? Capital, talent and market access to name a few. In 2019, MA biopharma companies raised $3.1B in venture capital. Even during COVID times, they have still been able to raise more than $2. This year there have been 7 IPOs, representing one-third of all biotech IPOs in the US. There has been a nearly 20% increase in biotech R&D jobs in the past year so it is talent rich. About 10% of all NIH funding goes to MA and they get more per-capita than any other state. Also, 54% of NIH hospital funding goes to facilities there. Currently, in MA there are 2,056 drug candidates representing 12% of the entire US pipeline and more are coming. It sounds great but you have to be smart. We will examine some of the ways to improve your odds of successfully navigating this terrain to achieve your goals.
Dawn Hocevar - President and CEO at BioCT the bioscience cluster of Connecticut
BioCT is dedicated to growing the vibrant bioscience ecosystem in Connecticut by supporting innovation, collaboration, networking, education, talent engagement and advocacy. We bring together companies, institutions, entrepreneurs, investors, government, service providers, and other passionate, dedicated people, to create a thriving community to improve patients’ lives and public health and drive economic growth.
Dieter Lingelbach - Chief Business Officer at SIRION Biotech
Dieter has been acting for over 9 years with SIRION Biotech as its Managing Director in charge of Business Development, Communication and Finance. He has a longstanding general management experience with both Roche Diagnostics and MorphoSys. Today, the latter is one of the world’s leading bio-technology companies on the basis of its proprietary antibody platform. Earlier, Dieter worked several years with Booz & Company’s healthcare practice after receiving his MBA from Indiana University as a Fulbright Scholar.
SIRION Biotech expanded into France and USA in 2018 and 2019 respectively. Dieter shares his experiences with the USA since then; Munich based, he acts as President SIRION Biotech International, Inc. in Cambridge, MA.
About SIRION BioTech
SIRION Biotech GmbH is Europe’s leading commercial supplier of viral vector technologies, offering the most comprehensive portfolio of custom viral vectors at shortest timelines and with the most professional personal project management services.
The company began business in 2007 in Martinsried, Germany and since then has been changing the paradigm of viral vector supplies. SIRION vectors are being used for gene function research, preclinical target validation, gene therapy & vaccine development. SIRION technologies are licensed for several major clinical trials in Europe and US (Phases I and III).
The flyer and detailed agenda for the BioM-WebSeminar "International Market Access Series - Go USA" can be downloaded (pdf). The WebSeminar will be held in English.
The seminar is free to attend but electronic registration is necessary.
Dr. Andreas Berghammer and Anja Weber
BioM Biotech Cluster Development GmbH
E-mail: berghammer@E-mail: bio-m.org weber@ bio-m.org
Phone: +49 (0) 89-899679-17 Phone: +49 (0) 89-899679-35